Momenta Pharmaceuticals Inc (NASDAQ:MNTA) saw a big move last session, as the company’s shares fell by nearly 17% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the most recent downtrend for MNTA as the stock is now down over 28% since March 19. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares after opening at $11.52 moved to $12.13 on last trade day and at the end of the day closed at $11.11. Company price to sales ratio in past twelve months was calculated as 16.42 and price to cash ratio as 2.37. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) showed a negative weekly performance of -22.63%.
KaloBios Pharmaceuticals Inc (NASDAQ:KBIO)’s share price has entered into oversold territory with an RSI value of 29.9. The Zacks Consensus Estimate for KaloBios for the full year period has improved 8 cents over the past two months to -$1.40 per share. Currently, KaloBios has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( KBIO ) after its recent drop. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) shares fell -4.17% in last trading session and ended the day on $2.53. KBIO return on equity ratio is recorded as -393.90% and its return on assets is -91.30%. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) yearly performance is -57.83%.
Wedbush initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI) in a research note issued on Monday, TheFlyOnTheWall.com reports. The firm set an “underperform” rating and a $10.00 price target on the stock. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares moved down -3.10% in last trading session and was closed at $10.95 while trading in range of $10.75 – $11.38 – Infinity Pharmaceuticals Inc. (NASDAQ:INFI) year to date (YTD) performance is -20.71%.
AMAG Pharmaceuticals, Inc (NASDAQ:AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the 13thAnnual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. ET in New York. The session will include a company presentation followed by a question and answer session, in which the company’s business and financial outlook, strategy and growth prospects will be discussed. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) weekly performance is -1.38%. On last trading day company shares ended up $18.64. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) distance from 50-day simple moving average (SMA50) is -10.32%. Analysts mean target price for the company is $25.14.
Leave a Reply